Luxendo, a start-up company launched by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM) in Heidelberg announced today the closing of a EUR 6 Million Series A financing co-led by EMBL Ventures, Heidelberg and Life Science Partners (LSP), Amsterdam. Dr Stefan Herr, Partner at EMBL Ventures and Dr. Joachim Rothe, Partner at LSP will join Luxendo Board.
EMBL has been at the forefront of microscope technology development worldwide for decades. Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. As compared to other existing light microscope technologies, SPIM uses for the first time a thin light sheet instead of a focussed light beam for sample illumination. The resulting plane illumination allows immediate and faster registration and acquisition of objects rather than the former slow beam spot scanning technology. Compared to modern state of the art confocal or wide-field microscopes, SPIM technology allows for significantly reduced sampling times (factor 1000x) at comparable and even higher resolution with highly reduced damaging side effects on the living objects investigated. SPIM technology was 2015 characterized “Method of the Year” by Nature Science.